Circulating soluble Fas levels and risk of ovarian cancer

BMC Cancer

Volumn 3, Issue , 2003, Pages

  Akhmedkhanov, Arslan ^a   Lundin, Eva ^b   Guller, Seth ^a   Lukanova, Annekatrin ^b,e   Micheli, Andrea ^c   Ma, Yeuhong ^a   Afanasyeva, Yelena ^a   Zeleniuch Jacquotte, Anne ^a   Krogh, Vittorio ^c   Lenner, Per ^b   Muti, Paola ^d   Rinaldi, Sabina ^e   Kaaks, Rudolf ^e   Berrino, Franco ^c   Hallmans, Göran ^b   Toniolo, Paolo ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY AT BUFFALO   (United States)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Apoptosis; CD95 blood; Epidemiology; Ovarian neoplasms; Prospective cohorts; sFas

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BLOOD DONOR; BLOOD LEVEL; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CIRCULATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; EPITHELIUM; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SWEDEN; UNITED STATES; BLOOD; MIDDLE AGED; OVARY TUMOR;

ANTIGENS, CD95; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 3042707293     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-3-33     Document Type: Article

References (21)

1. Society American Cancer: Cancer Facts & Figures - 2003. American Cancer Society, Inc 2003.
2. Gatta G, Lasota MB, Verdecchia A: Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer 1998, 34:2218-2225.
3. Ghahremani M, Foghi A, Dorrington JH: Etiology of ovarian cancer: a proposed mechanism. Med Hypotheses 1999, 52:23-26.
4. Baldwin RL, Tran H, Karlan BY: Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol 1999, 74:265-271.
5. Nagata S, Golstein P: The Fas death factor. Science 1995, 267:1449-1456.
6. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP: Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 1995, 94:1-8.
7. Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C: Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000, 96:65-69.
8. Konno R, Takano T, Sato S, Yajima A: Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000, 6:3576-3580.
9. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996, 56:3870-3874.
10. Toniolo PG, Pasternack BS, Shore RE, Sonnenschein E, Koenig KL, Rosenberg C, Strax P, Strax S: Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 1991, 18 Suppl 1:S23-S26.
11. Chajes V, Hulten K, Van Kappel AL, Winkvist A, Kaaks R, Hallmans G, Lenner P, Riboli E: Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. Int J Cancer 1999, 83:585-590.
12. Muti P, Pisani P, Crosignani P, Micheli A, Panico S, Secreto G, Berrino F: ORDET - prospective study on hormones, diet and breast cancer: feasibility studies and long-term quality control. Steroids 1988, 52:395-396.
13. Greendale GA, Sowers M: The menopause transition. Endocrinol Metab Clin North Am 1997, 26:261-277.
14. Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Muti P, Zeleniuch-Jacquotte A, Biessy C, Lenner P, Krogh V, Berrino F, Hallmans G, Riboli E, Kaaks R: Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 2002, 99:603-608.
15. Liang KY, Zeger SL: Longitudinal data-analysis using generalized linear models. Biometrika 1986, 73:13-22.
16. Michels KB, Greenland S, Rosner BA: Does body mass index adequately capture the relation of body composition and body size to health outcomes? Am J Epidemiol 1998, 147:167-172.
17. French LE, Tschopp J: Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002, 12:51-55.
18. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K: Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000, 82:1446-1452.
19. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH: Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995, 85:1562-1569.
20. Mountz JD, Zhou T, Su X, Wu J, Cheng J: The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol 1996, 80:S2-14.
21. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999, 20:46-52.